30th Mar 2005 07:01
LiDCO Group Plc30 March 2005 For immediate release 30 March 2005 LiDCO GROUP PLC ("LiDCO") Lithium Chloride Mutual Recognition Approval in Denmark LiDCO Group plc, (AIM: LID) the UK-based cardiovascular monitoring company, ispleased to announce today that a further European approval of Lithium Chloridefor use with the LiDCOplus System has been granted in Denmark. Lithium Chlorideis used in conjunction with the LiDCOplus System to provide an absolute measureof a patients cardiac output. This latest registration now provides LiDCO with full marketing approval in aportfolio of thirteen European countries including UK, Spain, Germany, Austria,Italy, Czech Republic, Belgium and Holland, Ireland, Norway, Sweden, Bulgariaand Denmark. Commenting on the approval in Denmark, Dr Terry O'Brien, LiDCO's CEO, said:"Following on from the recent approvals in Ireland, Norway, Sweden and Bulgariawe have now registered the lithium chloride injection as a pharmaceutical(in-vivo diagnostic) in a further European market. Europe is the most developedterritory for the adoption of advanced minimally invasive cardiovascularmonitoring and with this extended group of territories we expect the growth inEuropean sales to be further accelerated in 2005." For further information please contact: LiDCO Group PlcTerry O'Brien (CEO) [email protected] 020 7749 1500 Buchanan CommunicationsTim Anderson, Mary-Jane Johnson, James Strong 020 7466 5000 Notes for Editors LiDCO is a leading developer of minimally invasive, computer-based hemodynamicmonitoring equipment and disposables used primarily for the management ofcritical care and cardiovascular risk hospital patients. The Company's currentproducts are: • the LiDCOplus and PulseCO monitors, computer-based platforms for displaying a range of real-time continuous hemodynamic parameters including cardiac output, oxygen delivery and fluid volume; and • the LiDCO disposable for accurately determining cardiac output in a minimally-invasive manner. Lithium dilution calibrated waveform analysis The LiDCOplus monitor uses arterial pressure waveform analysis, in conjunctionwith Lithium dilution cardiac output calibration. Lithium does not occurnaturally in the body. Making this a patentable reference indicator. Theinjected lithium is used in trace amounts as an in vivo diagnostic, not atherapeutic drug, to calibrate the PulseCO continuous beat to beat software.The measurement of the marker lithium ion concentration in blood is made througha proprietary lithium selected ion sensor attached to existing radial or otherperipheral arterial lines. The lithium is injected into the venous circulationvia a central venous or peripheral venous line. The lithium cardiac outputdetermination is then used to calibrate cardiac output continuously from thearterial pulse power profile of the pressure waveform. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
LID.L